Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
5Customers
2Debt Items
12Related Chains
Source-Backed Evidence Depth
Nkarta, Inc. (NKTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
3Distinct source URLs
7High confidence
0.776Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Nkarta, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LICENSORS
LICENSORS
92%
Payments to the Licensors pursuant to the license agreement include single-digit royalty payments on commercial sales, a portion of any sublicensing revenue, patent expenses, license maintenance fees…
THIRD-PARTY-CONTRACT-MANUFACTURING-SITES
THIRD-PARTY-CONTRACT-MANUFACTURING-SITES
90%
we currently manufacture clinical supply of NKSTIM cells and the gamma-retrovirus at third-party contract manufacturing sites.
NATIONAL-UNIVERSITY-OF-SINGAPORE
NATIONAL-UNIVERSITY-OF-SINGAPORE
80%
If our license agreement with National University of Singapore and St. Jude Children’s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK-cell engineeri…
ST-JUDE-CHILDREN-S-RESEARCH-HOSPITAL-INC
ST-JUDE-CHILDREN-S-RESEARCH-HOSPITAL-INC
80%
If our license agreement with National University of Singapore and St. Jude Children’s Research Hospital, Inc. is terminated, we could lose our rights to key components enabling our NK-cell engineeri…
Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as all of the other information co…
Reciprocal relationship from CRSP graph: Reciprocal relationship from NKTX graph: Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should careful…
Item 1A. Risk Factors. An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as all of the other information co…
CVC-GROUP
CVC-GROUP
62%
, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our drug candidates, delays, suspension or withdrawal of…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
th our obligations under European privacy laws will be sufficient. Legal developments affecting cross-border data transfer mechanisms, including challenges to the validity of transfer frameworks or c…
RESEARCH-HOSPITAL-INC
RESEARCH-HOSPITAL-INC
62%
ary statements. i RISK FACTOR SUMMARY Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all the risks…
Nkarta, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NKTX-DEBT
Debt stack $75.0M
90%
Market cache reports total debt of $75.0M.
NKTX-DEBT-11283
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Nkarta, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nkarta, Inc..
Nkarta, Inc. Ownership
Holder
Name
Confidence
Evidence
NKTX-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 125 tracked holders.
